Nd revising of the manuscript. A.K.: Surgeon on many of the instances, CC-90005 Inhibitor involved in drafting and revising in the manuscript. L.H.L.: Oncologist. Every single patient was discussed in the interdisciplinary panel and the decision to treat was according to this, involved in drafting and revising in the manuscript. S.N.: Reviewing the radiotherapy and deciding which patient to treat or to not treat, involved in drafting and revising from the manuscript. T.K.: Pathologist reviewing the pathologic investigations, involved in drafting and revising on the manuscript. C.B.: Assistant surgeon on lots of from the cases, reviewer of the manuscript, involved in drafting and revising on the manuscript. A.B.-M.: Radiologist reviewing the radiologic investigations, involved in drafting and revising with the manuscript. H.R.D.: Corresponding author. Created the study notion, did the final information evaluation and supplied the key clinical input in writing and revising of the manuscript. Attending surgeon specialized in Orthopedic Oncology. Every author has contributed considerably to, and is prepared to take public duty for this study: its design and style, information acquisition, and analysis and interpretation of data. All authors have read and agreed for the published version on the manuscript. Funding: This analysis received no external funding. Institutional Review Board Statement: This study was authorized by the ethics committee with the Health-related Faculty, University of Munich (17-891, February 2018). Informed Consent Statement: Informed consent was obtained from all surviving patients integrated within this study. For non-surviving Oprozomib Autophagy individuals, data have been irreversibly anonymized, as suggested by the ethics committee. Data Availability Statement: The datasets applied and/or analyzed in the course of the existing study are offered in the corresponding author on reasonable request. Conflicts of Interest: All authors have no monetary and private relationships with other persons or organizations that could inappropriately influence (bias) this work.AbbreviationsAI: Adriamycin and Ifosfamid; CTX: chemotherapy; CT: computed tomography; DFS: illness free of charge survival; EIA: Etoposid, Ifosamid and Adriamycin; ESMO: European Society of Health-related Oncology; FNCLCC: F ation Nationale des Centres de Lutte Contre le Cancer; G1, G2, G3: Grading based on the French Federation of Cancer Centers grading system; Gy: Gray; LR: local recurrence; LRFS: nearby recurrence cost-free survival; MRI: Magnetic resonance imaging; NCCN: National Extensive Cancer Network; NIH: National Institute of Well being; n.s.: not significant; R0, R1, R2: resection margin; RTX: radiotherapy; OS: overall survival; STS: soft tissue sarcomas; TMCC: Toronto Margin Context Classification; UICC: Union internationale contre le cancer.
agronomyArticleThe Productivity of Cassava (Manihot esculenta Crantz) in Kagoshima, Japan, Which Belongs for the Temperate ZoneShin Yabuta 1 , Tamami Fukuta 1 , Shotaro Tamaru two , Keita Goto 2 , Yoshihiro Nakao 1 , Phanthasin Khanthavong 2,three , Peter Ssenyonga 4,5 and Jun-Ichi Sakagami 1, 3Faculty of Agriculture, Kagoshima University, Kagoshima 890-0065, Japan; [email protected] (S.Y.); [email protected] (T.F.); [email protected] (Y.N.) The United Graduate College of Agricultural Sciences, Kagoshima University, Kagoshima 890-0065, Japan; [email protected] (S.T.); [email protected] (K.G.); [email protected] (P.K.) National Agriculture and Forestry Study Institute, Vientiane 7170, Laos Graduate Sch.
